Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

2022 Genitourinary Cancers Symposium

17 - 19 Feb 2022
Moscone West, San Francisco, United States of America
ASCO GU 2022: Prostate roundup
Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore
ASCO GU 2022: Prostate roundup ( Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore )
20 Apr 2022
ASCO GU 2022: Latest in mHSPC
Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith
ASCO GU 2022: Latest in mHSPC ( Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith )
8 Mar 2022
ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE
Dr Neal Shore and Prof Kim Chi
ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE ( Dr Neal Shore and Prof Kim Chi )
4 Mar 2022
An AI-derived digital pathology-based biomarker to predict the benefit of ADT in...
Prof Daniel Spratt - University Hospitals Seidman Cancer Center, Cleveland, USA
An AI-derived digital pathology-based biomarker to predict the benefit of ADT in PC with validation in NRG/RTOG 9408 ( Prof Daniel Spratt - University Hospitals Seidman Cancer Center, Cleveland, USA )
3 Mar 2022
SG in combination with pembro in patients with mUC who progressed after platinum...
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
SG in combination with pembro in patients with mUC who progressed after platinum (PLT)-based regimens ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )
28 Feb 2022
NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion
Prof Sam Chang - Vanderbilt University School of Medicine, Nashville, USA
NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion ( Prof Sam Chang - Vanderbilt University School of Medicine, Nashville, USA )
28 Feb 2022
Latest developments in mHSPC
Prof Kurt Miller and Prof Laura-Maria Krabbe
Latest developments in mHSPC ( Prof Kurt Miller and Prof Laura-Maria Krabbe )
25 Feb 2022
Evaluating a polygenic hazard score to predict risk of developing metastatic or ...
Dr Meghana Pagadala - University of California San Diego, San Diego, USA
Evaluating a polygenic hazard score to predict risk of developing metastatic or fatal prostate cancer ( Dr Meghana Pagadala - University of California San Diego, San Diego, USA )
25 Feb 2022
ASCO GU 2022: The latest in CRPC, including PARP combo data
Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel Mers...
ASCO GU 2022: The latest in CRPC, including PARP combo data ( Prof Eleni Efstathiou, Prof Gerhardt Attard, Prof Noel Clarke and Prof Axel Merseburger )
25 Feb 2022
Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma o...
Dr Hielke Martijn de Vries - Netherlands Cancer Institute, Amsterdam, The Nether...
Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis ( Dr Hielke Martijn de Vries - Netherlands Cancer Institute, Amsterdam, The Netherlands )
24 Feb 2022
Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in a...
Dr Cristina Suárez - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spai...
Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in aRCC ( Dr Cristina Suárez - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
21 Feb 2022
KEYNOTE 564 update: Pembrolizumab versus placebo as post-nephrectomy adjuvant th...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
KEYNOTE 564 update: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
21 Feb 2022
ASCO GU 2022: What to watch out for in renal
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ASCO GU 2022: What to watch out for in renal ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
21 Feb 2022
Maintenance PARP inhibition following chemotherapy for metastatic urothelial car...
Dr Simon Crabb - University of Southampton, Southampton, UK
Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma ( Dr Simon Crabb - University of Southampton, Southampton, UK )
21 Feb 2022
First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients...
Prof Alfredo Berruti - University Of Brescia, Brescia, Italy
First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study. ( Prof Alfredo Berruti - University Of Brescia, Brescia, Italy )
21 Feb 2022
Durvalumab with olapirib shows no PFS improvement for platinum-ineligible bladde...
Prof Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA
Durvalumab with olapirib shows no PFS improvement for platinum-ineligible bladder cancer ( Prof Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA )
21 Feb 2022